ArticleMolecular biology reports2025
Silencing lncRNA MCM3AP-AS1 protects against cisplatin-induced cell death in A549 lung cancer cells.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundLung cancer remains the leading cause of cancer-related mortality worldwide, largely due to the development of resistance to standard chemotherapeutic agents such as cisplatin. Recent evidence has highlighted the regulatory role of long non-coding RNAs (lncRNAs) in mediating drug resistance mechanisms. In this study, we aimed to reveal the role of MCM3AP-AS1 in cisplatin-induced cell death in lung cancer cells. METHODS AND
resultsAs a result, we found that MCM3AP-AS1, a lncRNA previously associated with poor prognosis in various cancers, was significantly upregulated in A549 lung cancer cells following cisplatin treatment. Using RNA interference-mediated silencing of MCM3AP-AS1, we observed a marked increase in cell viability and a decrease in apoptosis, as determined by MTT assay, annexin V/PI flow cytometry, and acridine orange/ethidium bromide staining.
conclusionsThese findings suggest that MCM3AP-AS1 may be a crucial modulator of cisplatin-induced apoptosis in lung cancer cells.
Indexed as
Identifiers
40660060What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.